[1]
|
Thompson, B. and Hales, C. (2014) Overview of Acute Pulmonary Embolism.
http://www.uptodate.com/contents/overview-of-acute-pulmonary-embolism?source=search_result& search=PE%2Fdvt&selectedTitle=4%7E150
|
[2]
|
Anderson Jr., F.A., Zayaruzny, M., Heit, J.A., Fidan, D. and Cohen, A.T. (2007) Estimated Annual Numbers of US Acute-Care Hospital Patients at Risk for Venous Thromboembolism. American Journal of Hematology, 82, 777-782.
http://dx.doi.org/10.1002/ajh.20983
|
[3]
|
Dismuke, S. and Wagner, E. (1986) Pulmonary Embolism as a Cause of Death. The Changing Mortality in Hospitalized Patients. JAMA, 255, 2039. http://dx.doi.org/10.1001/jama.1986.03370150081032
|
[4]
|
Horlander, K.T., Manninom, M. and Leeper, KV. (2003) Pulmonary Embolism Mortality in the United States, 1979- 1998: An Analysis Using Multiple-Cause Mortality Data. Archives of Internal Medicine, 163, 1711.
http://dx.doi.org/10.1001/archinte.163.14.1711
|
[5]
|
Chisholm-Burns, M., Wells, B., Schwinghammer, T., Malone, P., Kolesar, J., Rotschafer, J. and Dipiro, J. (2008) Pharmacotherapy: Principles & Practice. The McGraw-Hill Companies, Inc., New York.
|
[6]
|
Khan, S., Dunn, A., Klein, R., et al. (2012) Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST, 141, e195S-e226S. http://dx.doi.org/10.1378/chest.11-2296
|
[7]
|
Scaglione, L., Piobbici, M., Pagano, E., Ballini, L., Tamponi, G and Ciccone, G. (2005) Implementing Guidelines for Venous Thromboembolism Prophylaxis in a Large Italian Teaching Hospital: Lights and Shadows. Haematologica, 90, 678-684.
|
[8]
|
Bateman, A., Sheaff, R., Child, S., et al. (2013) The Implementation of NICE Guidelines on Venous Thromboembolism Risk Assessment and Prophylaxis; A Before-After Observational Study to Assess the Impact on Patient Safety Across Four Hospitals in England. BioMed Central, 13, 1-7.
|
[9]
|
CPOE: Cerner.com. http://www.cerner.com/solutions/Hospitals_and_Health_Systems/CPOE/
|
[10]
|
Decousus, H., Tapson, V., Bergmann, J., et al. (2011). Factors at Admission Associated With Bleeding Risk in Medical Patients; Findings from the IMROVE Investigators. CHEST, 139, 69-79. http://dx.doi.org/10.1378/chest.09-3081
|
[11]
|
Leizorovicz, A., Cohen, A.T., Turpie, A.G., Olsson, C.G., Vaitkus, P.T. and Goldhaber, S.Z. (2004) Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. Circulation, 110, 874-879. http://dx.doi.org/10.1161/01.CIR.0000138928.83266.24
|
[12]
|
Samama, M., Cohen, T, Darmon, J., et al. (1999) A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. New England Journal of Medicine, 341, 793-800. http://dx.doi.org/10.1056/nejm199909093411103
|
[13]
|
Jetha, L. (2007) A Drug Usage Review of Therapeutic Doses of Enoxaparin at Barnet and Chase Farm Hospitals. London Pharmacy Education and Training Pzifer Project Awards.
http://www.londonpharmacy.nhs.uk/educationandtraining/prereg/pfizerProjectAwards2007/leila%20 jetha%20Barnet%20and%20Chase%20Farm%20Hospital%20Trust.pdf
|
[14]
|
Pugh, M., Fincke, B., Bierman, A., et al. (2005) Potentially Inappropriate Prescribing in Elderly Veterans: Are We Using the Wrong Drug, Wrong Dose, or Wrong Duration? Journal of the American Geriatrics Society, 53, 1282-1289. http://dx.doi.org/10.1111/j.1532-5415.2005.53402.x
|
[15]
|
Yu, H., Dylan, M., Lin, J. and Dubois, R. (2007) Hospitals’ Compliance with Prophylaxis Guidelines for Venous Thromboembolism. American Journal of Health-System Pharmacy, 64, 69-76. http://dx.doi.org/10.2146/ajhp060115
|
[16]
|
Selby, R. and Geerts, W. (2009) Prevention of Venous Thromboembolism: Consensus, Controversies, and Challenges. American Society of Hematology, 2009, 286-292. http://dx.doi.org/10.1182/asheducation-2009.1.286
|
[17]
|
Coutre, S. (2014) Clinical Presentation and Diagnosis of Heparin-Induced Thrombocytopenia.
http://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-heparin-inducedthrombocytopenia?source=search_result&search=HITT&selectedTitle=1%7E150
|
[18]
|
Lo, G.K., Juhl, D., Warkentin, T., Sigouin, C., Eicheler, P. and Greinacher, A. (2004) Evaluation of Pretest Clinical Score (4 T's) for the Diagnosis of Heparin-Induced Thrombocytopenia in Two Clinical Settings. Journal of Thrombosis and Haemostasis, 4, 759-765. http://dx.doi.org/10.1111/j.1538-7836.2006.01787.x
|
[19]
|
Duplaga, B., Rivers, C. and Nutescu, E. (2001). Dosing and Monitoring of Low-Molecular-Weight Heparins in Special Populations. Pharmacotherapy, 21, 218-234. http://dx.doi.org/10.1592/phco.21.2.218.34112
|
[20]
|
King, C., Holley, A., Jackson, J., Shorr, A. and Moores, L. (2007) Twice Daily vs Three Times Daily Heparin Dosing for Thromboembolism Prophylaxis in the General Medical Population. CHEST, 131, 507-516.
http://dx.doi.org/10.1378/chest.06-1861
|
[21]
|
Nutescu, E., Spinler, S., Wittkowsky, A. and Dager, W. (2009) Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations across Medical and Surgical Settings. Annals of Pharmacotherapy, 43, 1064-1083. http://dx.doi.org/10.1345/aph.1L194
|
[22]
|
Phung, O., Kahn, S., Cook, D. and Murad, M. (2011) Dosing Frequency of Unfractionated Heparin Thromboprophylaxis: A Meta-Analysis. CHEST, 140, 374-381. http://dx.doi.org/10.1378/chest.10-3084
|
[23]
|
Scholten, D., Hoedema, R. and Scholten, S. (2002) A Comparison of Two Different Prophylactic Dose Regimens of Low Molecular Weight Heparin in Bariatric Surgery. Obesity Surgery, 12, 19-24.
http://dx.doi.org/10.1381/096089202321144522
|
[24]
|
Enoxaparin. In: DRUGDEX® System (internet database). Thomson Micromedex, Greenwood Village, Colorado, USA.
http://www.thomsonhc.com
|
[25]
|
Enoxaparin: Drug information. (2013).
http://www.uptodate.com/contents/enoxaparin-drug-information?source=search_result&search=enoxaparin&selectedTitle=1%7E96
|